Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ephedrine alkaloids 8 mg per serving limit "too high," state food, drug officials say.

This article was originally published in The Tan Sheet

Executive Summary

EPHEDRINE ALKALOIDS 8 MG/SERVING FDA PROPOSED LIMIT "TOO HIGH," the Association of Food and Drug Officials maintains in Nov. 22 comments to FDA on the agency's June 4 proposed rule on dietary supplements containing the ingredients. AFDO, which represents state food and health department officials, says the proposed limit of 8 mg per serving is "too high and should be substantially reduced." Setting the level at 8 mg, "where life- threatening adverse events `can reasonably be expected to occur,'" as FDA says, "does not adequately protect consumers and sets a dangerous precedent for a `standard of adulteration' for dietary supplements," AFDO says.

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

People In Brief

Perrigo promotes in pricing, planning

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS087872

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel